Emren S.V.Zoghi M.Berilgen R.Özdemir İ.H.Çelik O.Çetin N.Enhoş A.Köseoğlu C.Akyüz A.Doğan V.Levent F.Dereli Y.Doğan T.Başaran Ö.Karaca I.Karaca Ö.Otlu Y.Ö.Özmen Ç.Coşar S.Sümerkan M.Gürsul E.İnci S.Onrat E.Ergene O.2024-07-222024-07-22201815128601http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/15121Once-daily dosing of non-vitamin K antagonist oral anticoagulants (NOACs) may increase patient adherence to treatment but may also be associated with a higher risk of bleeding. In this study, we investigated the adherence to once-or twice-daily dosing of NOACs and the risk of bleeding in nonvalvular atrial fibrillation (NVAF) patients. This multicenter cross-sectional study, conducted between 1 September 2015 and 28 February 2016, included 2214 patients receiving NOACs for at least 3 months, due to NVAF. Patients receiving once-daily or twice-daily NOAC doses were 1:1 propensity score matched for baseline demographic characteristics and the presence of other diseases. The medication adherence was assessed by the 8-item Morisky Medication Adherence Scale. Risk factors were investigated in relation to minor and major bleeding. The mean age of patients was 71 ± 10 years, and 53% of the patients were women. The medication adherence was lower in patients receiving twice-daily NOAC doses compared to once-daily-dose group (47% versus 53%, p = 0.001), and there was no difference between the groups in terms of minor (15% versus 16%, p = 0.292) and major bleeding (3% versus 3%, p = 0.796). Independent risk factors for bleeding were non-adherence to medication (OR: 1.62, 95% CI: 1.23–2.14, p = 0.001), presence of 3 or more other diseases (OR: 10.3, 95% CI: 5.3–20.3, p < 0.001), and HAS-BLED (Hypertension, Abnormal renal and liver function, Stroke, Bleeding, Labile INR, Elderly, Drugs or alcohol) score (OR: 4.84, 95% CI: 4.04–5.8, p < 0.001). In summary, the once-daily dose of NOACs was associated with increased patient adherence to medication, while it was not associated with bleeding complications. © 2018 ABMSFBIH.EnglishAll Open Access; Gold Open AccessAdministration, OralAgedAnticoagulantsAtrial FibrillationCross-Sectional StudiesDabigatranFemaleHemorrhageHumansMaleMedication AdherenceMiddle AgedPatient SafetyPyrazolesPyridonesRetrospective StudiesRisk FactorsRivaroxabanStrokeTurkeyanticoagulant agentapixabandabigatranpyrazole derivativepyridone derivativerivaroxabanagedatrial fibrillationbleedingcerebrovascular accidentclinical trialcomplicationcross-sectional studyfemalehumanmalemedication compliancemiddle agedmulticenter studyoral drug administrationpatient safetyretrospective studyrisk factorturkey (bird)Article10.17305/bjbms.2017.2279